Skip to content
value.today

OncoCyte Corp

Total raised
$22 M
3 rounds on record
Latest round
$11 M
Aug 2016
First round on record
May 2015
Today
Went public
See the company page

OncoCyte Corp is listed today as Insight Molecular Diagnostics Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 6 other private sales on record. Open the number of investors for the round's details.

Funding rounds of OncoCyte Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2025$22 MPrivate placement after listing$10 to $50 million

OncoCyte Corp: Private sale, Feb 2025

Investors in this round

12 investors had bought by the notice of Feb 24, 2025: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Andrea James · Executive Officer · Chief Financial Officer
  • James Liu · Executive Officer · Senior Director, Controller & Principal Accounting Officer
  • Joshua Riggs · Executive Officer, Director · President and Chief Executive Officer and Director
  • Andrew Arno · Director
  • Andrew Last · Director
  • Louis Silverman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “The Company did not engage a placement agent.”

Signed by Joshua Riggs, President and Chief Executive Officer and Director. Source: SEC Form D, newest notice filed Feb 24, 2025. Read the notice at the SEC.

equity, optionsSEC
Oct 2024$10 MPrivate placement after listing$10 to $50 million

OncoCyte Corp: Private sale, Oct 2024

Investors in this round

16 investors had bought by the notice of Oct 8, 2024: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$250,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in California

People named in the notice

  • Andrea James · Executive Officer · Chief Financial Officer
  • James Liu · Executive Officer · Senior Director, Controller & Principal Accounting Officer
  • Joshua Riggs · Executive Officer, Director · President and Chief Executive Officer and Director
  • Andrew Arno · Director
  • Andrew Last · Director
  • Louis Silverman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Needham & Company, LLC (CRD 000016360) · New York, New YorkSold in NY

Signed by Joshua Riggs, President and Chief Executive Officer and Director. Source: SEC Form D, newest notice filed Oct 8, 2024. Read the notice at the SEC.

equitySEC
Apr 2024$16 MPrivate placement after listing$10 to $50 million

OncoCyte Corp: Private sale, Apr 2024

Investors in this round

21 investors had bought by the notice of Apr 25, 2024: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$250,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in California

People named in the notice

  • James Liu · Executive Officer, Director · Controller, Principal Accounting Officer and interim Principal Financial Officer
  • Joshua Riggs · Executive Officer, Director · President and Chief Executive Officer and Director
  • Alfred Kingsley · Director
  • Andrew Arno · Director
  • Andrew Last · Director
  • Louis Silverman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Needham & Company, LLC (CRD 000016360) · New York, New YorkSold in NY

Signed by /s/ Joshua Riggs, President and Chief Executive Officer and Director. Source: SEC Form D, newest notice filed Apr 25, 2024. Read the notice at the SEC.

equity, optionsSEC
Apr 2021$3 MPrivate placement after listing$2 to $10 million

OncoCyte Corp: Private sale, Apr 2021

Investors in this round

75 investors had bought by the notice of Apr 29, 2021: 75 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $18 M offered; $14 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Douglas T Ross · Executive Officer
  • Mitchell A Levine · Executive Officer
  • Padmavathi T Sundar · Executive Officer
  • Ronald A Andrews · Executive Officer, Director
  • Alfred D Kingsley · Director
  • Andrew J Last · Director
  • Andy Levin Arno · Director
  • Cavan T Redmond · Director
  • Jennifer Levin Carter · Director
  • Melinda Levin Griffith · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ronald Andrews, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 29, 2021. Read the notice at the SEC.

equitySEC
Feb 2021$5 MPrivate placement after listing$2 to $10 million

OncoCyte Corp: Private sale, Feb 2021

Investors in this round

7 investors had bought by the notice of Mar 8, 2021: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Douglas T Ross · Executive Officer
  • Mitchell A Levine · Executive Officer
  • Padmavathi T Sundar · Executive Officer
  • Ronald A Andrews · Executive Officer, Director
  • Alfred D Kingsley · Director
  • Andrew J Last · Director
  • Andy Levin Arno · Director
  • Cavan T Redmond · Director
  • Jennifer Levin Carter · Director
  • Melinda Levin Griffith · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mitchell Levine, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 8, 2021. Read the notice at the SEC.

equitySEC
Jan 2020$5 MPrivate placement after listing$2 to $10 million

OncoCyte Corp: Private sale, Jan 2020

Investors in this round

29 investors had bought by the notice of Feb 11, 2020: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $11 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Albert Parker · Executive Officer
  • Mitch Levine · Executive Officer
  • Ronald Andrews · Executive Officer, Director
  • Aditya Mohanty · Director
  • Alfred Kingsley · Director
  • Andrew Arno · Director
  • Andrew Last · Director
  • Cavan Redmond · Director
  • Melinda Griffith · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Contingent consideration of up to $6,000,000 additional shares may be issued to investors.”

Signed by Mitch Levine, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 11, 2020. Read the notice at the SEC.

equitySEC
Aug 2016$11 MNo. 3$10 to $50 million

OncoCyte Corp: Raise no. 3, Aug 2016

Investors in this round

9 investors had bought by the notice of Sep 9, 2016: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$511,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in California

People named in the notice

  • Russell Skibsted · Executive Officer
  • William Annett · Executive Officer, Director
  • Aditya Mohanty · Director
  • Alfred Kingsley · Director
  • Andrew Arno · Director
  • Andrew Last · Director
  • Cavan Redmond · Director
  • Don Bailey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cowen & Company, LLC (CRD 7616) · New York, New YorkSold in CA, NY, PA

Remarks in the notice

  • On fees: “Cowen & Company paid $511,000 to act as placement agent for the Issuer.”
  • On the amounts: “Total Amount Sold does not include Common Stock Warrants totaling 3,246,153 that were issued upon closing.”

Signed by Judith Segall, Corporate Secretary. Source: SEC Form D, newest notice filed Sep 9, 2016. Read the notice at the SEC.

equity, optionsSEC
Sep 2015$8 MNo. 2$2 to $10 million

OncoCyte Corp: Raise no. 2, Sep 2015

Investors in this round

1 investor had bought by the notice of Oct 15, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $11 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$787,500 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in California

People named in the notice

  • Karen B. Chapman · Executive Officer
  • Kristine C. Mechem · Executive Officer
  • Robert W. Peabody · Executive Officer, Director
  • William Annett · Executive Officer, Director
  • Aditya D. Mohanty · Director
  • Alfred D. Kingsley · Director
  • Andrew W. Arno · Director
  • Cavan D. Redmond · Director
  • Michael D. West · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total offering = 7,370,609 shares / Sold so far = 5,421,714 shares”

Signed by Judith Segall, Corporate Secretary. Source: SEC Form D, newest notice filed Oct 15, 2015. Read the notice at the SEC.

equitySEC
May 2015$3 MNo. 1$2 to $10 million

OncoCyte Corp: Raise no. 1, May 2015

Investors in this round

2 investors had bought by the notice of May 14, 2015: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for OncoCyte Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$1,000,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$285,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in California

People named in the notice

  • Joseph Wagner · Executive Officer, Director
  • Robert W. Peabody · Executive Officer, Director
  • Aditya D. Mohanty · Director
  • Alfred D. Kingsley · Director
  • Michael D. West · Director
  • William D. Annett · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Judith Segall, Corporate Secretary. Source: SEC Form D, newest notice filed May 14, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Insight Molecular Diagnostics Inc., its revenue in fiscal 2025 came from these product and service lines: Laboratory Services $4.03 million (99%), Kitted Products $20,000 (1%).

    Annual report (SEC XBRL) · Dec 2025

  • OncoCyte Corp chose not to state its revenue in its newest notice of a funding round (Feb 2025).

    SEC Form D · Feb 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2025

Products and services#

No products or services of OncoCyte Corp are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in OncoCyte Corp
InvestorKindAmountRoundRoleSource
John Peter GutfreundPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2022)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 9 investors.

Largest shareholders today

Institutions holding Insight Molecular Diagnostics Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by OncoCyte Corp
NameRoleNamed in
Andrea JamesChief Financial OfficerFeb 2025
James LiuSenior Director, Controller & Principal Accounting OfficerFeb 2025
Joshua RiggsPresident and Chief Executive Officer and DirectorFeb 2025
Douglas T RossExecutive officerApr 2021
Mitchell A LevineExecutive officerApr 2021
Padmavathi T SundarExecutive officerApr 2021
Ronald A AndrewsExecutive officerApr 2021
Albert ParkerExecutive officerFeb 2020
Mitch LevineExecutive officerFeb 2020
Ronald AndrewsExecutive officerFeb 2020
Russell SkibstedExecutive officerSep 2016
William AnnettExecutive officerSep 2016
Karen B. ChapmanExecutive officerOct 2015
Kristine C. MechemExecutive officerOct 2015
Robert W. PeabodyExecutive officerOct 2015
Joseph WagnerExecutive officerMay 2015
Andrew ArnoDirectorFeb 2025
Andrew LastDirectorFeb 2025
Joshua RiggsPresident and Chief Executive Officer and DirectorFeb 2025
Louis SilvermanDirectorFeb 2025
Alfred KingsleyDirectorApr 2024
James LiuController, Principal Accounting Officer and interim Principal Financial OfficerApr 2024
Alfred D KingsleyDirectorApr 2021
Andrew J LastDirectorApr 2021
Andy Levin ArnoDirectorApr 2021
Cavan T RedmondDirectorApr 2021
Jennifer Levin CarterDirectorApr 2021
Melinda Levin GriffithDirectorApr 2021
Ronald A AndrewsDirectorApr 2021
Aditya MohantyDirectorFeb 2020
Cavan RedmondDirectorFeb 2020
Melinda GriffithDirectorFeb 2020
Ronald AndrewsDirectorFeb 2020
Don BaileyDirectorSep 2016
William AnnettDirectorSep 2016
Aditya D. MohantyDirectorOct 2015
Alfred D. KingsleyDirectorOct 2015
Andrew W. ArnoDirectorOct 2015
Cavan D. RedmondDirectorOct 2015
Michael D. WestDirectorOct 2015

Went public since 2016. Its SEC number is that of a company listed on a stock exchange.